Adamo Valle

Dr. Adamo Valle

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Molecular Cell
Verified
Journal Article
Closed access
LBLaia Bosch-Presegué
Laia Bosch-Presegué
HRHelena Raurell-Vila
Helena Raurell-Vila
AMAnna Marazuela-Duque
Anna Marazuela-Duque
NKNoriko Kane-Goldsmith
Noriko Kane-Goldsmith
AVAdamo Valle
Adamo Valle
AVAlejandro Vaquero
Alejandro Vaquero

1 March 2017 in Molecular Cell
Verified
Journal Article
Open access
AGAmit Gupta
Amit Gupta
SASara Anjomani-Virmouni
Sara Anjomani-Virmouni
NKNikos Koundouros
Nikos Koundouros
MDMaria Dimitriadi
Maria Dimitriadi
RCRayman Choo-Wing
Rayman Choo-Wing
GPGeorge Poulogiannis
George Poulogiannis
PARK2 is a gene implicated in disease states with opposing responses in cell fate determination, yet its contribution in pro-survival signaling is largely unknown. Here we show that PARK2 is altered in over a third of all human cancers, and its depletion results in enhanced phosphatidylinositol 3-kinase/Akt (PI3K/Akt) activation and increased vulnerability to PI3K/Akt/mTOR inhibitors. PARK2 depletion contributes to AMPK-mediated activation of endothelial nitric oxide synthase (eNOS), enhanced levels of reactive oxygen species, and a concomitant increase in oxidized nitric oxide levels, thereby promoting the inhibition of PTEN by S-nitrosylation and ubiquitination. Notably, AMPK activation alone is sufficient to induce PTEN S-nitrosylation in the absence of PARK2 depletion. Park2 loss and Pten loss also display striking cooperativity to promote tumorigenesis in vivo. Together, our findings reveal an important missing mechanism that might account for PTEN suppression in PARK2-deficient tumors, and they highlight the importance of PTEN S-nitrosylation in supporting cell survival and proliferation under conditions of energy deprivation.

1 January 2009 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RGRocío Guevara
Rocío Guevara
FSFrancisca M. Santandreu
Francisca M. Santandreu
AVAdamo Valle
Adamo Valle
MGMagdalena Gianotti
Magdalena Gianotti
Jordi OliverJordi Oliver
Jordi Oliver
Pilar RocaPilar Roca
Pilar Roca

1 September 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
DPDaniel Gabriel Pons
Daniel Gabriel Pons
MNMercedes Nadal-Serrano
Mercedes Nadal-Serrano
MTMargalida Torrens-Mas
Margalida Torrens-Mas
AVAdamo Valle
Adamo Valle
Jordi OliverJordi Oliver
Jordi Oliver
Pilar RocaPilar Roca
Pilar Roca

1 January 2011 in Cellular Physiology and Biochemistry
Verified
Journal Article
Closed access
FSFrancisca M. Santandreu
Francisca M. Santandreu
AVAdamo Valle
Adamo Valle
Jordi OliverJordi Oliver
Jordi Oliver
Pilar RocaPilar Roca
Pilar Roca
The treatment of advanced colorectal cancer with 5-fluorouracil has two major problems: development of tumor resistance and toxicity toward normal tissues. The aim of this study was to investigate the possible advantages of combining 5-fluorouracil (5-FU) with resveratrol (trans-3, 4', 5-trihydroxystilbene) for treating HT-29 and SW-620 colorectal carcinoma cell lines. Since combined treatment using 5-FU with resveratrol resulted in a significant decrease in long-term cell survival, we investigated the possible basis of this synergistic interaction at a molecular level, focusing on oxidative stress as a possible mediator of cell death. Resveratrol established interactions with the mitochondria of cancer cells and induced an imbalance in cellular antioxidant activities, leading to a significant increase in the levels of both intracellular reactive oxygen species (ROS) and lipid peroxides. Combined treatment with resveratrol sensitized colon cancer cells to 5-fluorouracil, inducing a further increase in oxidative stress, which was linked to the inhibition of AKT and STAT3 proteins, which are known to have oncogenic potential in colorectal carcinomas.

15 February 2010 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
Jorge Sastre-SerraJorge Sastre-Serra
Jorge Sastre-Serra
AVAdamo Valle
Adamo Valle
MCMaria Margarita Company
Maria Margarita Company
IGIsabel Garau
Isabel Garau
Jordi OliverJordi Oliver
Jordi Oliver
Pilar RocaPilar Roca
Pilar Roca